Perspective Therapeutics, Inc. CATX R2KR3KPHARMA
Company Overview
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -72.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -9.99% |
| 1 Year: | -72.10% |
Stock Price Performance
| 1 Year: | -57.74% |
| 6 Months: | -64.30% |
| 3 Months: | -42.91% |
| 1 Month: | -35.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.26 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -10.0% CAGR over 5 years.
- Trading 71.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CATX Perspective Therapeutics, Inc. R2KR3KPHARMA | 1.61 | -1.21 | $183.78M | 0.00% | -47.66% | -39.57% | -9.99% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.08M | 1.03M | 1.28M | 1.37M | 1.21M | 1.54M | 1.57M | 1.60M | 1.56M | 1.90M | 1.92M | 1.92M | 2.31M | 2.21M | 2.88M | 2.28M | 2.38M | 2.36M | 2.60M | 2.71M | 2.56M | 2.82M | 2.91M | 2.50M | 1.72M | 2.06M | 2.09M | 2.19M | - | - | - | - | - | - | - | - |
| Gross Profit | 83.00K | 30.00K | 66.00K | -48.00K | 48.00K | -1.00K | 293.00K | 498.00K | 265.00K | 531.00K | 609.00K | 443.00K | 524.00K | 765.00K | 879.00K | 879.00K | 1.24M | 1.11M | 1.71M | 1.07M | 1.25M | 1.17M | 1.36M | 1.35M | 1.03M | 1.22M | 1.44M | 926.00K | 414.00K | 487.00K | 248.00K | 738.00K | - | - | - | - | - | - | - | - |
| Operating Income | -1.09M | -1.41M | -1.33M | - | -1.57M | -1.48M | -1.39M | - | -1.55M | -1.47M | -1.34M | - | -1.52M | -1.43M | -1.16M | - | -836.00K | -903.00K | -548.00K | - | -714.00K | -873.00K | -766.00K | - | -2.27M | -1.64M | -1.38M | -2.11M | -4.21M | -9.76M | -9.75M | -9.75M | -13.01M | -14.26M | -18.63M | -21.83M | -24.04M | -27.86M | -28.28M | -29.26M |
| Net Income | -1.02M | -1.31M | -1.20M | -1.19M | -1.50M | -1.45M | -1.36M | -1.85M | -1.55M | -1.46M | -1.33M | -2.34M | -1.51M | -1.41M | -1.13M | -1.09M | -816.00K | -897.00K | -545.00K | -1.19M | -713.00K | -868.00K | -745.00K | -1.06M | -2.24M | -1.60M | -1.35M | -2.08M | -4.07M | -371.00K | -11.11M | -10.36M | -12.28M | -11.70M | -15.12M | -18.18M | -21.48M | -25.97M | -26.19M | -26.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | -0.40 | -0.37 | -0.25 | -0.18 | -0.21 | -0.25 | -0.29 | -0.35 | -0.25 | -0.22 |
| R&D Expense | 144.00K | 58.00K | 183.00K | - | 172.00K | 150.00K | 327.00K | - | 362.00K | 340.00K | 473.00K | - | 420.00K | 414.00K | 299.00K | - | 233.00K | 277.00K | 294.00K | - | 312.00K | 285.00K | 362.00K | - | 702.00K | 535.00K | 549.00K | 796.00K | 708.00K | 3.31M | 5.37M | 5.55M | 7.45M | 9.28M | 12.03M | 14.33M | 16.62M | 20.34M | 21.37M | 21.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.07M | 4.53M | 4.22M | 4.61M | 4.77M | 4.76M | 5.92M | 7.31M | 9.68M | 10.05M | 10.79M | 0 | 1.43M | - | - |
| Gross Profit | 703.20K | 150.18K | -196.47K | 167.00K | 129.00K | 838.00K | 1.84M | 3.05M | 5.12M | 5.12M | 0 | 0 | 1.43M | - | - |
| Operating Income | -3.60M | -4.07M | -4.59M | -4.34M | -5.08M | -6.31M | -6.73M | -5.25M | -3.48M | -3.45M | -6.42M | -8.67M | -40.94M | -90.89M | -113.56M |
| Net Income | -3.49M | -3.86M | -5.96M | -3.68M | -4.71M | -6.16M | -6.70M | -5.14M | -3.45M | -3.39M | -7.27M | -10.76M | -46.51M | -79.28M | -103.12M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -1.74 | -1.23 | -1.40 |
| R&D Expense | 780.58K | 627.11K | 668.80K | 615.00K | 528.00K | 965.00K | 1.75M | 1.47M | 1.13M | 1.43M | 850.00K | 881.00K | 21.31M | 41.64M | 84.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.51M | 7.06M | 26.55M | 23.00M | 18.10M | 12.27M | 7.46M | 9.42M | 8.70M | 70.42M | 64.44M | 58.09M | 97.89M | 341.10M | 266.97M |
| Total Equity | 6.45M | 5.82M | 5.37M | 23.96M | 20.78M | 16.40M | 10.60M | 5.03M | 7.68M | 5.72M | 67.41M | 61.28M | 54.64M | 75.18M | 290.67M | 207.03M |
| Cash & Equivalents | 2.11M | 2.67M | 2.90M | 7.68M | 5.23M | 10.14M | 5.93M | 2.60M | 5.33M | 2.39M | 63.83M | 55.89M | 20.99M | 9.24M | 61.58M | 30.63M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.73M | 1.68M | 1.62M |
| Total Liabilities | - | 1.69M | 1.69M | 2.59M | 2.22M | 1.70M | 1.67M | 2.42M | 1.74M | 2.98M | 3.01M | 3.16M | 3.45M | 22.71M | 50.43M | 59.94M |
| Current Liabilities | - | 648.99K | 792.87K | 1.15M | 1.09M | 1.09M | 1.11M | 1.83M | 1.12M | 1.57M | 1.80M | 2.27M | 3.12M | 15.66M | 18.23M | 28.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.45M | -3.06M | - | - | -3.88M | -5.71M | -5.71M | -5.05M | -3.64M | -2.84M | -7.71M | -10.40M | -36.91M | -18.29M | -82.48M |
| Investing Cash Flow | -95.52K | -12.82K | - | - | 8.76M | 1.51M | 1.86M | 401.00K | -287.00K | -410.00K | -284.00K | -28.99M | 24.37M | -218.93M | 41.23M |
| Financing Cash Flow | 3.10M | 3.30M | - | - | 39.00K | -9.00K | 521.00K | 7.37M | 994.00K | 64.68M | 56.00K | 28.00K | 785.00K | 289.38M | 10.30M |
| Capital Expenditure | -55.06K | -6.58K | -19.03K | -133.00K | -479.00K | -549.00K | -337.00K | -444.00K | -273.00K | -381.00K | -266.00K | -282.00K | -1.07M | -54.41M | -12.75M |
| Free Cash Flow | -2.50M | -3.06M | - | - | -4.36M | -6.26M | -6.05M | -5.49M | -3.91M | -3.22M | -7.98M | -10.68M | -37.98M | -72.71M | -95.23M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 13.9% | 3.3% | -4.7% | 3.6% | 2.7% | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | 0.0% | - | 100.0% | - | - |
| Operating Margin % | -71.0% | -89.9% | -108.7% | -94.2% | -106.6% | -132.5% | -113.6% | -71.8% | -35.9% | -34.3% | -59.5% | - | -2,855.0% | - | - |
| Net Margin % | -68.8% | -85.2% | -141.2% | -79.9% | -98.8% | -129.4% | -113.1% | -70.3% | -35.6% | -33.7% | -67.4% | - | -3,243.2% | - | - |
| ROE % | -60.0% | -71.9% | -24.9% | -17.7% | -28.7% | -58.1% | -133.2% | -67.0% | -60.2% | -5.0% | -11.9% | -19.7% | -61.9% | -27.3% | -49.8% |
| ROCE % | -52.5% | -64.9% | -18.1% | -19.8% | -29.9% | -56.5% | -119.7% | -63.3% | -48.8% | -5.0% | -10.3% | -15.8% | -49.8% | -28.1% | -47.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.32% | 9.49M | $25.25M |
| 2 | TCG Crossover Management, LLC | 6.93% | 7.92M | $21.06M |
| 3 | Commodore Capital Lp | 5.55% | 6.34M | $16.86M |
| 4 | Avidity Partners Management, LP | 5.52% | 6.30M | $16.76M |
| 5 | State Street Corporation | 5.30% | 6.05M | $16.10M |
| 6 | Millennium Management Llc | 4.30% | 4.91M | $13.07M |
| 7 | Vanguard Capital Management LLC | 3.89% | 4.44M | $11.80M |
| 8 | Affinity Asset Advisors, Llc | 3.69% | 4.21M | $11.21M |
| 9 | Citadel Advisors Llc | 3.33% | 3.81M | $10.12M |
| 10 | Spruce Street Capital LP | 3.24% | 3.69M | $9.83M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CATX
$CATX stock is down 27% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPN0pKWHJ5VUFaRXV6NkQtTXQ3dDIyaEJHa00wd2JnWlFha3Y4SFlPdWJnbGRlcU54bzdRNGdmVXdDcWtZZmt6bjdmZ2d1ZTZKTXZhUFVtcFAtWkJMaTNEa3N3eWxJbU85a1MyeU8tYW1ROXo5cEJINWlMeUhicjFhY0FvYXpzLUFESG1NLT…
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOUmZtT2R1T0pZLXgwMTJOd0ttYUhoSE1kZnZRNTN4aEVCdGxrRzhfcUZnNGJYSi1fb0doMUFqcS1FSEFSVGJkRlJ5bHdBWThTaG1ZN3FPUEFxbFlnci1OQXpEa1RGdTlJVmpta0NYajQxWkJCWmFFdDlOYUpEb01hbl9PXzJXWFZEY20zWV…
Half of one group had tumor responses, including unconfirmed cases, in a cancer trial. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOMkg1VzF5SjlDWTVQV3Y3TC11dGZfaWlsdFRKbzF6QUxYcTNLUWdPLXBiZkdpeVdwaDF4anRqRHJSV3JPY01TaFVQWk5KV01TNlBjM3NsNXI4RE9DOUhvX1dFUUZXM01xQ1NiZGs2a0dJZGIybDhleUxLQlBJRmN5ZkdNczB2dGV6V29pbW…
CATX: ORR reached 50% in Cohort 3, with 71.9% PFS at 18 months across cohorts - TradingView
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPN242dDA5WFlHYlgzLWtUNHNaWWtqSDN6MTVPX0lMVmdlNGJNOEZqWENWYXpQZWhtaVhXM0R5cmhXUTBEZmR4Qnp0U0ZEZjVOaG9Lc3BfQ0pXUzlpb3FkS1N5eURFUUdBZ1BPWko1ME5KR3U1ZW5GaUpfbmh4bUcyU2Y0b2FhUmstVFlVYl…
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOVGQwMnlETmdLanhFRnltRVkwU2gxVFdqbFpDWVMxMDRCVE1MSW9MZWQ3b0U5bm5sZU1xZUR6Y2xYS0tvSUxxTVE1OXNBeThmM2JxdlNKSU5COFNuOXJzcWVCQWNQMmg5cWNqTFRjLUV0Zl83cmlwU0h5ZEdoa3NXMWhGelQ5WWVNV3prS3…
CATX Nov 2026 2.500 put (CATX261120P00002500) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5xcFRBeUpMNlN0Tnh1cTVJUDRYNUlTUEdRVkt0Y0ZwU0FFdV9xejd4anJSTlBpaHplakNhTldfdjFUYXNncDhKTVIxM2tidlVmcUNOb3JrbVltV3o2dTk1QmpTR2d3Zw?oc=5" target="_blank">CATX Nov 2026 2.500 put (CATX…
CATX — Frequently Asked Questions
What is the current share price of Perspective Therapeutics, Inc. (CATX)?
As of 2026-10-23 16:27 PDT, Perspective Therapeutics, Inc. (CATX) trades at $1.61 on NYSE American. Its 52-week range is $1.61 to $5.65.
What is the market capitalisation of CATX?
Perspective Therapeutics, Inc. (CATX) has a market capitalisation of $183.78M on NYSE American.
What is the P/E ratio of CATX?
CATX trades at a trailing price-to-earnings (P/E) ratio of -1.21. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.94.
What is the return on equity (ROE) of CATX?
CATX has a return on equity (ROE) of -39.57%. Its return on capital employed (ROCE) is -47.66%.
Is CATX a good stock to buy?
This page provides a data-driven analysis of Perspective Therapeutics, Inc. (CATX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.